109 related articles for article (PubMed ID: 11054353)
1. Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration.
Canteros-Picotto A; Fernández-Martín JL; Cannata-Andía JB
Am J Kidney Dis; 2000 Nov; 36(5):969-75. PubMed ID: 11054353
[TBL] [Abstract][Full Text] [Related]
2. Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
Menéndez-Fraga P; Fernández-Martín JL; Blanco-González E; Cannata-Andía JB
Clin Chem; 1998 Jun; 44(6 Pt 1):1262-8. PubMed ID: 9625051
[TBL] [Abstract][Full Text] [Related]
3. Estimation of aluminoxamine and ferrioxamine in plasma by high performance liquid chromatography.
Hughes H; Hagen LE; Cameron EC; Sutton RA
Clin Chim Acta; 1986 May; 157(1):115-20. PubMed ID: 3719992
[No Abstract] [Full Text] [Related]
4. Chromatographic studies of aluminum-desferrioxamine complex in uremic patients.
Canavese C; Pacitti A; Salomone M; Pramotton C; Segoloni G; Bedino S; Testore G; Lamon S; Vercellone A
ASAIO Trans; 1986; 32(1):367-9. PubMed ID: 3778736
[No Abstract] [Full Text] [Related]
5. Ultrafiltration studies in vitro of serum aluminum in dialysis patients after deferoxamine chelation therapy.
Leung FY; Hodsman AB; Muirhead N; Henderson AR
Clin Chem; 1985 Jan; 31(1):20-3. PubMed ID: 3965214
[TBL] [Abstract][Full Text] [Related]
6. Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis.
Vasilakakis DM; D'Haese PC; Lamberts LV; Lemoniatou E; Digenis PN; De Broe ME
Kidney Int; 1992 May; 41(5):1400-7. PubMed ID: 1614055
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of aluminoxamine and feroxamine chelates in dialysis patients.
Canavese C; Gurioli L; D'Amicone M; Cardelli R; Caligaris F; Bongiorno P; Arnaud A; Mattiello G; Marchiori M
Nephron; 1992; 60(4):411-7. PubMed ID: 1584315
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients.
Verpooten GA; D'Haese PC; Boelaert JR; Becaus I; Lamberts LV; De Broe ME
Nephrol Dial Transplant; 1992; 7(9):931-8. PubMed ID: 1328941
[TBL] [Abstract][Full Text] [Related]
9. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients.
Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A
Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000
[No Abstract] [Full Text] [Related]
10. Desferrioxamine in the treatment of aluminum overload.
Ackrill P; Day JP
Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
[TBL] [Abstract][Full Text] [Related]
11. Desferrioxamine and hemofiltration for aluminum removal in patients on regular dialysis treatment.
Segoloni G; Canavese G; D'Amicone M; Rubino GF; Scansetti G; Lamon S; Talarico S; Luda E; Vercellone A
Clin Nephrol; 1983 Aug; 20(2):105-8. PubMed ID: 6616975
[No Abstract] [Full Text] [Related]
12. Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients.
Andriani M; Nordio M; Saporiti E
Nephron; 1996; 72(2):218-24. PubMed ID: 8684530
[TBL] [Abstract][Full Text] [Related]
13. Ultrafiltrable aluminium after very low doses of desferrioxamine.
Canteros A; Díaz-Corte C; Fernández-Martín JL; Gago E; Fernández-Merayo C; Cannata J
Nephrol Dial Transplant; 1998 Jun; 13(6):1538-42. PubMed ID: 9641189
[TBL] [Abstract][Full Text] [Related]
14. Urinary and biliary excretion of aluminoxamine and ferrioxamine in dogs with various renal function.
D'Haese PC; Lamberts LV; Verpooten GA; Vaneerdeweg W; Jurgens A; Arakelian S; Babloyan A; Digenis P; Tjalma W; De Broe ME
Kidney Int; 1994 Jan; 45(1):76-84. PubMed ID: 8127024
[TBL] [Abstract][Full Text] [Related]
15. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
Klemm A; Sperschneider H; Winnefeld K; Günther K; Stein G
Clin Nephrol; 1997 Feb; 47(2):133-4. PubMed ID: 9049466
[No Abstract] [Full Text] [Related]
16. Indirect measurement of desferrioxamine and its chelated compounds aluminoxamine and ferrioxamine by Zeeman atomic absorption spectrometry.
D'Haese PC; Lamberts LV; De Broe ME
Clin Chem; 1989 May; 35(5):884-7. PubMed ID: 2720988
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo comparative studies on chelation of aluminum by some polyaminocarboxylic acids.
Graff L; Muller G; Burnel D
Res Commun Mol Pathol Pharmacol; 1995 Jun; 88(3):271-92. PubMed ID: 8564384
[TBL] [Abstract][Full Text] [Related]
18. Aluminum-binding protein in dialysis dementia. II. Characterization in plasma by ultrafiltration.
Khalil-Manesh F; Agness C; Gonick HC
Nephron; 1989; 52(4):329-33. PubMed ID: 2770949
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation.
Molitoris BA; Alfrey PS; Miller NL; Hasbargen JA; Kaehney WD; Alfrey AC; Smith BJ
Kidney Int; 1987 Apr; 31(4):986-91. PubMed ID: 3586503
[TBL] [Abstract][Full Text] [Related]
20. Convective interaction media monolithic chromatography with ICPMS and ultraperformance liquid chromatography-electrospray ionization MS detection: a powerful tool for speciation of aluminum in human serum at normal concentration levels.
Murko S; Milacic R; Kralj B; Scancar J
Anal Chem; 2009 Jun; 81(12):4929-36. PubMed ID: 19435331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
